NanoPrecMed

Nanobioparticles for precision medicine

NanoPrecMed connects leading research institutions from Austria and the Czech Republic with the goal of jointly advancing the development of a competitive biotech/biopharma industry in the regions. The focus is on new diagnostic and therapeutic procedures for nanomedicine. The project promotes innovation, education, translation, and economic development in the Austrian-Czech border regions.

Project partners:

  • Mendel University,  Department of Chemistry and Biochemistry, Brno
  • Brno University of Technology, Faculty of Chemistry, Brno
  • Biology Centre CAS, České Budějovice
  • Johannes Kepler University, Linz
  • University of Applied Sciences Upper Austria
  • LBI Trauma (Lead Partner)

The NanoPrecMed consortium brings together six universities and research institutions from Vienna, Upper Austria, South Bohemia, and South Moravia. The goal is to use nanobioparticles (NBPs), tiny, biocompatible transporters for active ingredients and diagnostic markers, to develop new, precise therapies and diagnostic procedures, thus laying the foundation for a strong biotechnology/biopharmaceutical industry in the regions.

Despite excellent research facilities, the participating regions have so far lacked commercial implementation. NanoPrecMed closes this gap through knowledge and technology transfer, targeted training, and new academic-industrial collaborations.

The project is aimed at students, young researchers, company founders, and SMEs.

The project implements the following measures:

  • Joint training of students and young researchers
  • Interactive workshop formats for exchange, training, and networking
  • Development of concrete showcase applications
  • Establishment of a sustainable structure to continue our mission beyond the project term

The project strengthens the regional economy, brings innovation into practice, and opens career opportunities for young talent. The long-term vision: a competitive, cross-border biotech/biopharma landscape that retains talent, shares knowledge, and turns research into impact.

a.
a. The project logo shows the border line between the Czech Republic (blue) and Austria (red), above which are six building blocks symbolising the partner organisations working together within the project.

Project outputs:

NanoPrecMed has already achieved important milestones:

All six research institutions in the four regions are successfully collaborating in a structured consortium.

More than 50 participants have already taken part in cross-border workshops (Linz Winter School and NanoPrecMed OpenLab) in the first reporting period, promoting exchange, networking, and training.

Two scientific publications have already emerged from the project, and more are in preparation.

Public relations work is ongoing via a dedicated project website, LinkedIn and Instagram channels, and presentations at events.

Numerous SME contacts have already been established, and consultations have been initiated, for example, at the ISEV conference in Vienna.

Specific scientific projects are in progress: these include an mRNA-based vaccine against TBE, an extracellular vesicle that can specifically target cancer cells, and RNA nanoparticles for hepatitis B therapy.